About Jounce Therapeutics
Jounce Therapeutics is a company based in Cambridge (United States) founded in 2013 was acquired by Concentra Biosciences in March 2023. Jounce Therapeutics has raised $139 million across 4 funding rounds from investors including Celgene, Casdin Capital and Nextech Invest. The company has 137 employees as of December 31, 2021. Jounce Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Cambridge, United States
- Employees 137 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Jounce Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$139 M (USD)
in 4 rounds
-
Latest Funding Round
$35 M (USD), Post-IPO
Oct 29, 2020
-
Investors
Celgene
& 9 more
-
Employee Count
137
as on Dec 31, 2021
-
Acquired by
Concentra Biosciences
(Mar 27, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Jounce Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Jounce Therapeutics
Jounce Therapeutics has successfully raised a total of $139M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Jounce Therapeutics
Jounce Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Celgene, Casdin Capital and Nextech Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked |
Investor details for Jounce Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jounce Therapeutics
Investment portfolio details for Jounce Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Jounce Therapeutics
Detailed financials for Jounce Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Jounce Therapeutics Comparisons
Peer comparison for Jounce Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Jounce Therapeutics
Jounce Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Jounce Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jounce Therapeutics
Complete news archive for Jounce Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jounce Therapeutics
Jounce Therapeutics was founded in 2013.
Jounce Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jounce Therapeutics is a funded company, having raised a total of $139M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Jounce Therapeutics is 137.
Jounce Therapeutics was founded in 2013 in Cambridge, United States, as a clinical-stage immunotherapy company. Discovery and development of cancer treatments are focused on, with a pipeline emphasizing monoclonal antibodies. The lead candidate, JTX-2011, binds to Inducible T cell Co-Stimulator to activate immune responses against tumors. Studies on the tumor microenvironment, particularly tumor-associated macrophages, are conducted to advance potential immunotherapies across various cancers.
Jounce Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Jounce Therapeutics has 10 investors. Key investors include Celgene, Casdin Capital, Nextech Invest, Wellington, and Foresite Capital.